CD4 and classic Hodgkin lymphoma: However, the high response rates to CPIs, points to the fact that the activity of these drug in cHL is not based on the direct release of killer T-cell inhibition but rather on the recognition of cancer epitopes exposed on MHC-II molecules by CD4+ T-cells.